The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) hit a new 52-week low and has $2.96 target or 10.00% below today’s $3.29 share price. The 8 months bearish chart indicates high risk for the $46.68 million company. The 1-year low was reported on Sep, 30 by Barchart.com. If the $2.96 price target is reached, the company will be worth $4.67 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 40,849 shares traded hands. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has declined 67.01% since February 26, 2016 and is downtrending. It has underperformed by 77.44% the S&P500.
Analysts await Orexigen Therapeutics, Inc. (NASDAQ:OREX) to report earnings on November, 3. They expect $-1.23 EPS, down 36.67% or $0.33 from last year’s $-0.9 per share. After $-1.73 actual EPS reported by Orexigen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -28.90% EPS growth.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Ratings Coverage
Out of 5 analysts covering Orexigen Therapeutics (NASDAQ:OREX), 2 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 40% are positive. Orexigen Therapeutics has been the topic of 12 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, November 6. The rating was downgraded by JMP Securities on Wednesday, March 16 to “Market Perform”. JP Morgan maintained the stock with “Buy” rating in Monday, August 10 report. The firm has “” rating given on Tuesday, September 15 by RBC Capital Markets. On Wednesday, August 5 the stock rating was upgraded by Zacks to “Sell”. Bank of America reinitiated the stock with “Underperform” rating in Friday, December 11 report. The stock has “Overweight” rating given by Piper Jaffray on Tuesday, October 6. The firm has “Market Perform” rating by Wells Fargo given on Friday, December 4. Piper Jaffray maintained the shares of OREX in a report on Saturday, August 8 with “Buy” rating.
According to Zacks Investment Research, “OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company’s lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company’s understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.”
Insitutional Activity: The institutional sentiment decreased to 0.27 in 2016 Q2. Its down 0.46, from 0.73 in 2016Q1. The ratio is negative, as 42 funds sold all Orexigen Therapeutics, Inc. shares owned while 28 reduced positions. 9 funds bought stakes while 10 increased positions. They now own 61.80 million shares or 34.69% less from 94.63 million shares in 2016Q1.
Lmr Prtnrs Llp holds 0.01% or 127,844 shares in its portfolio. Cqs Cayman L P holds 113,000 shares or 0% of its portfolio. Royal State Bank Of Canada reported 7,200 shares or 0% of all its holdings. Moreover, California Pub Employees Retirement Sys has 0% invested in Orexigen Therapeutics, Inc. (NASDAQ:OREX) for 335,200 shares. Moreover, Ladenburg Thalmann Financial Inc has 0% invested in Orexigen Therapeutics, Inc. (NASDAQ:OREX) for 850 shares. Susquehanna Intl Llp last reported 114,630 shares in the company. Alpine Prns Vi Ltd Llc holds 0.03% or 138,774 shares in its portfolio. Samlyn Lc holds 0.06% of its portfolio in Orexigen Therapeutics, Inc. (NASDAQ:OREX) for 6.16 million shares. Foresite Cap Ii holds 1.6% or 5.43 million shares in its portfolio. Stifel Fincl holds 0% or 30,100 shares in its portfolio. The United Kingdom-based Barclays Public Ltd has invested 0% in Orexigen Therapeutics, Inc. (NASDAQ:OREX). Deutsche Savings Bank Ag has invested 0% of its portfolio in Orexigen Therapeutics, Inc. (NASDAQ:OREX). Bvf Il last reported 0.48% of its portfolio in the stock. Proshare Advsr Lc has 0% invested in the company for 108,358 shares. Janney Montgomery Scott Limited accumulated 0% or 50,565 shares.
More notable recent Orexigen Therapeutics, Inc. (NASDAQ:OREX) news were published by: Fool.com which released: “Blame This for Orexigen Therapeutics, Inc.’s Mind-Numbingly Bad 2015” on January 08, 2016, also Prnewswire.com with their article: “Orexigen Therapeutics Announces Commercialization and Distributorship …” published on August 30, 2016, Prnewswire.com published: “Orexigen Therapeutics Announces Stockholder Approval of All Proposals at 2016 …” on July 08, 2016. More interesting news about Orexigen Therapeutics, Inc. (NASDAQ:OREX) were released by: Prnewswire.com and their article: “Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth …” published on April 25, 2016 as well as Fool.com‘s news article titled: “Why Orexigen Therapeutics, Inc.’s Stock Is Losing Weight Today” with publication date: November 06, 2015.
OREX Company Profile
Orexigen Therapeutics, Inc., incorporated on September 12, 2002, is a biopharmaceutical company. The Firm is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.